DHAI (DIH Holding US) 3-Year EBITDA Growth Rate: 0.00% (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is DIH Holding US 3-Year EBITDA Growth Rate?

DIH Holding US DHAI 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2025.

DIH Holding US's EBITDA per Share for the three months ended in Mar. 2025 was $-3.22.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

DIH Holding US  (OTCPK:DHAI) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

DIH Holding US 3-Year EBITDA Growth Rate Related Terms

DHAI vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison

For the Medical Devices subindustry, DIH Holding US's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DIH Holding US 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, DIH Holding US's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where DIH Holding US's 3-Year EBITDA Growth Rate falls into.


DIH Holding US 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
DIH Holding US (DHAI) has a 3-Year EBITDA Growth Rate of 0.00% as of Mar. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DIH Holding US and its competitors.
Is DIH Holding US's 3-Year EBITDA Growth Rate too high?
DIH Holding US's current 3-Year EBITDA Growth Rate is 0.00%.
How does DIH Holding US's 3-Year EBITDA Growth Rate compare to ABT and SYK?
DIH Holding US's 3-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Medical Devices & Instruments industry. The industry median 3-Year EBITDA Growth Rate is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.90, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for DIH Holding US and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DIH Holding US's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DIH Holding US stock overvalued right now?
DIH Holding US (DHAI) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For DIH Holding US (DHAI), the current 3-Year EBITDA Growth Rate is 0.00% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DIH Holding US Business Description

Address 77 Accord Park Drive, Suite D-1, Norwell, MA, USA, 02061
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. It serves the healthcare systems, clinics, third-party healthcare providers, distributors and other institutions by providing a broad array of devices and services focused on the customer and patient recovery. Its key products are LokoMat, Erigo, Armeo, C-Mill and CAREN/Grail. Geographically, the company derives revenue from the EMEA, Americas, and Asia Pacific regions. The company generates revenue from the sale of medical rehabilitation devices and technology.